U.S. Asthma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Anti-inflammatory, Bronchodilators), By Device Type (Inhalers, Nebulizers), By Route of Administration (Oral, Inhaled), By Product, And Segment Forecasts, 2025 - 2033

Market Size & Trends

The U.S. asthma therapeutics market size was estimated at USD 13.00 billion in 2024 and is projected to reach USD 19.20 billion by 2033, growing at a CAGR of 4.5% from 2025 to 2033. The rising number of asthma patients in the U.S. has led to a growing demand for effective therapies, including some of the most advanced and promising treatment options.

The U.S. asthma therapeutics market is experiencing steady growth, driven by a rising number of asthma cases. According to the American Lung Association, over 25 million people in the U.S. are living with asthma, and approximately 5-10% of them have severe asthma, highlighting the urgent need for more effective and targeted treatment options.Although various therapies are available, many patients continue to experience frequent asthma attacks, highlighting the limitations of current medications. In response, pharmaceutical companies invest in developing advanced therapies that offer targeted and more effective solutions.

In February 2023, Amgen and AstraZeneca announced that the U.S. FDA approved TEZSPIRE for patients aged 12 years and older suffering from severe asthma. It has been approved for self-administration in the U.S. with a new prefilled pen. The product is also approved in the U.S., Japan, the EU, and other countries.

The increasing emphasis on precision medicine and patient-specific treatment plans is notably transforming asthma care markedly in the U.S. There is increasing interest in biomarkers and genetic profiling to effectively guide therapy decisions as healthcare shifts toward a more individualized approach. The changing scenario lets doctors spot the true sources of asthma for each patient and then choose the treatments that have the greatest effect. In addition, artificial intelligence and data analytics are being integrated into clinical practice. This integration improves diagnostic accuracy in addition to monitoring treatment. These particular clinical and technological advancements are not only enhancing therapeutic outcomes. Still, they are also creating new opportunities for pharmaceutical innovation, positioning the U.S. asthma therapeutics market for sustained, innovation-driven growth.

U.S. Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. asthma therapeutics market report based on drug class, device type, product, route of administration.

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Anti- inflammatory
• Bronchodilators
• Combination therapy
• Device Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Inhalers
• Nebulizers
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Dry Powder
• Metered Dose
• Soft Mist
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Inhaled
• Intravenous

Please note The report will be delivered in 2-3 business days upon order notification. Show more